Advertisement
Canada markets close in 4 hours 55 minutes
  • S&P/TSX

    21,949.35
    +63.97 (+0.29%)
     
  • S&P 500

    5,107.28
    +58.86 (+1.17%)
     
  • DOW

    38,227.26
    +141.46 (+0.37%)
     
  • CAD/USD

    0.7309
    -0.0015 (-0.20%)
     
  • CRUDE OIL

    83.46
    -0.11 (-0.13%)
     
  • Bitcoin CAD

    87,554.85
    +782.52 (+0.90%)
     
  • CMC Crypto 200

    1,331.17
    -65.37 (-4.68%)
     
  • GOLD FUTURES

    2,343.80
    +1.30 (+0.06%)
     
  • RUSSELL 2000

    1,998.01
    +16.90 (+0.85%)
     
  • 10-Yr Bond

    4.6590
    -0.0470 (-1.00%)
     
  • NASDAQ

    15,955.44
    +343.68 (+2.20%)
     
  • VOLATILITY

    15.39
    +0.02 (+0.13%)
     
  • FTSE

    8,138.08
    +59.22 (+0.73%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6839
    +0.0018 (+0.26%)
     

Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating the investigational Lenti-D gene therapy for the treatment of cerebral adrenoleukodystrophy (or CALD) in boys aged 17 years or less. The Phase 2/3 Starbeam study met its enrollment goal with the data reported by Bluebird Bio as of April 25. Thirty-one patients were studied, and 29 of them received Lenti-D gene therapy.